Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherBrief Communication

Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer

Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo and Irene J. Virgolini
Journal of Nuclear Medicine January 2023, jnumed.122.264977; DOI: https://doi.org/10.2967/jnumed.122.264977
Elisabeth von Guggenberg
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Uprimny
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maximilian Klingler
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris Warwitz
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Sviridenko
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steffen Bayerschmidt
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianpaolo Di Santo
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene J. Virgolini
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.122.264977
DOI 
https://doi.org/10.2967/jnumed.122.264977
PubMed 
36657979

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online January 19, 2023.

Copyright & Usage 
Copyright © 2023 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Elisabeth von Guggenberg,
  2. Christian Uprimny,
  3. Maximilian Klingler,
  4. Boris Warwitz,
  5. Anna Sviridenko,
  6. Steffen Bayerschmidt,
  7. Gianpaolo Di Santo and
  8. Irene J. Virgolini
  1. Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  1. For correspondence or reprints contact: Elisabeth von Guggenberg, Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Anichstrasse 35, Innsbruck 6020, Austria. E-mail: elisabeth.vonguggenberg@tirol-kliniken.at

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: January 2023 to February 2023

AbstractFullPdf
Jan 20231022042
Feb 2023561021
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (3)
Journal of Nuclear Medicine
Vol. 64, Issue 3
March 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Brief Communication

  • Novel 68Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls
  • Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy
Show more Brief Communication

Clinical (Oncology: Endocrine/Neuroendocrine)

  • The emergence of somatostatin antagonist-based theranostics: Paving the road toward another success?
  • Efficacy and safety of 124I-mIBG dosimetry-guided high activity 131I-mIBG therapy of advanced pheochromocytoma or neuroblastoma
Show more Clinical (Oncology: Endocrine/Neuroendocrine)

Similar Articles

Keywords

  • Oncology: Endocrine
  • Peptides
  • PET/CT
  • cholecystokin-2 receptor
  • gallium-68
  • medullary thyroid cancer
  • Minigastrin
  • Positron Emission Tomography
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire